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surement and, in the case of detection of a suspicious fo-
cus of a certain size, additional radiological investigation 
by CT or MRI and, if HCC was confirmed by imaging or 
biopsy, a decision to treat. This surveillance-step combi-
nation was still maintained at the Asian Oncology Sum-
mit 2009  [3] , by the WGO guideline from 2010  [4] and 
was even extended by the Japanese Society of Hepatology, 
which, for surveillance other than ultrasound, recom-
mended three biomarkers (AFP, AFP-L3 and DCP) every 
3–4 months [for hepatitis B virus (HBV)-related or HCV-
related cirrhosis] or every 6 months (for chronic hepatitis 
B/C or cirrhosis of other etiology)  [5, 6] . In the last prac-
tice guideline of the American Association for the Study 
of Liver Diseases (AASLD) from 2010  [7, 8] , surveillance 
of patients at risk for HCC was recommended only 
6-monthly by ultrasound, omitting AFP and the algo-
rithm for small nodules changed by <1 cm in diameter 
(3-monthly control) and >1 cm (4-phase multidetector-
row CT, dynamic contrast-enhanced MRI or, in the case 
of an untypical result for HCC, a biopsy). A similar clini-
cal practice HCC guideline was published this year by the 
European Association for the Study of the Liver, Euro-
pean Organization for Research and Treatment of Cancer 
(EASL-EORTC)  [9] . It is of note that one of the biggest 
American working groups for medical practice guide-
lines, the National Comprehensive Cancer Network 
(NCCN), evaluating most of their recommendations as 
evidence category 2A plus strength of consensus, has 
 Since the first description of α-fetoprotein (AFP) as 
the main serum and tissue tumor marker for hepatocel-
lular carcinoma (HCC) in the 1960s and its detection in 
germ cell tumors, a tremendous number of clinical stud-
ies have investigated this biomarker – particularly in pa-
tients with benign chronic liver diseases – up to the de-
velopment of HCC. The limitations that emerged in-
spired the search for additional markers intended as 
adjuncts for a combination with AFP in order to improve 
the utility in the clinical setting. According to an updated 
broad review from the National Academy of Clinical Bio-
chemistry (NACB) laboratory medicine practice guide-
lines for the use of tumor markers in different tumor en-
tities including liver cancer  [1] , only AFP was recom-
mended as the best investigated biomarker in the 
screening and early detection of patients at a high risk of 
HCC, for determining prognosis and for the monitoring 
of treatment. Among numerous other biomarkers, the fu-
cosylated fraction of AFP (AFP-L3), des-gamma-car-
boxyprothrombin (DCP) or PIVKA II (prothrombin 
produced by vitamin K absence or antagonism II, com-
prehensive review in  [2] ) and glypican 3 (GPC-3), espe-
cially, were judged as upcoming markers needing further 
investigation. The most critical application in HCC was, 
and still is, the surveillance of patients at a high risk of 
HCC and a reaction upon increased suspicion. Former 
recommendations in the USA and Europe included sur-
veillance by ultrasound in combination with AFP mea-
 Published online: February 8, 2013 
 Prof. Dr. Rolf Lamerz 
 Medical Department II, Klinikum Campus Grosshadern, Ludwigs-Maximilians-University 
 Marchionini-Strasse 15 
 DE–81377 München (Germany) 
 E-Mail rolf.lamerz   @   med.uni-muenchen.de 





















   
   
   
   
   
   
   
   
   
   
   





















 Are Biomarkers Still Helpfull in HCC? Digestion 2013;87:118–120
DOI: 10.1159/000346282
119
maintained (even in their most recent HCC guideline, 
version 2.2012) surveillance of patients at risk for HCC by 
ultrasound and AFP every 6–12 months, and considers a 
rising AFP level, besides liver mass or nodule, an indica-
tion for liver imaging exploration  [10] . Recently, a long-
term study on HCC in advanced HCV using AFP, DCP 
and AFP-L3 in patients of the Hepatitis C Antiviral Long-
Term Treatment against Cirrhosis (HALT-C) trial disap-
pointed by detecting only mild-to-moderate elevations of 
all the biomarkers used and elevations more often in 
those patients with chronic hepatitis and advanced fibro-
sis than in HCC, thus qualifying the biomarkers as only 
poor predictors of HCC  [11] . In an AFP study in surveil-
lance of compensated cirrhotic patients for small HCC 
detection, they were deemed similarly ineffective  [12] . 
However, a more recent French AFP study underscores a 
significant improvement of the performance of the Milan 
criteria concerning liver transplantation for HCC by the 
significant prediction of tumor recurrence by AFP  [13] . 
The search for new additional HCC biomarkers is ongo-
ing  [14] and has not yet been optimally resolved, although 
a prospective cohort study on small HCC using serum 
HCCR1  [15] looks promising, as does another on serum 
DKK1  [16] and a third on plasma osteopontin  [17] in 
combination with AFP.
 The secure detection of HCC in small biopsies >1cm 
in diameter is also not devoid of problems, in spite of 
more refined rules by an international working party clas-
sification and a final international consensus. In this re-
spect, the additional use of biomarkers has been suggest-
ed and is still under investigation  [18, 19] .
 In this issue, Ertle et al.  [20] present a prospective Ger-
man single-center cohort study on the conventional bio-
markers AFP and DCP, determined by a commercial as-
say conducted in a cohort of European patients with HCC 
of different etiology [n = 164; 18% had HBV, 17% had 
HCV, 14% were alcoholics, 21% had nonalcoholic steato-
hepatitis (NASH), 17% were cryptogenic and 74% had 
cirrhosis] and a control cohort of nonmalignant liver dis-
eases (n = 422; 55% had viral hepatitis, 19% had cirrhosis, 
others had NASH, primary sclerosing cholangitis and au-
toimmune hepatitis). The aim was to investigate the diag-
nostic contribution of AFP and DCP, via their single or 
combined use under cut-off optimization, and also their 
influence by examining clinical factors. Concerning sen-
sitivities for AFP ( ≥ 20 ng/ml) or DCP ( ≥ 7.5 ng/ml) re-
lated to HCC etiology, combined marker rates (AFP and/
or DCP) in all HCC cases increased from 53% (HBV) over 
74% (HCV) to 82–84% (NASH, alcoholic or cryptogenic 
etiology cases) which appears to underscore the higher 
detection rate of HCC by biomarkers in nonviral etiology. 
In the final evaluation at optimized cut-offs for AFP (10 
ng/ml) and DCP (5 ng/ml), the sensitivity rates for all 
HCC cases were 55% (AFP) or 64% (DCP) at almost 95% 
specificity, and in combination reached 78% at 89% spec-
ificity. For early stage HCC disease [72 TNM cases  ≤ 2 and 
48 Barcelona Clinic Liver Cancer (BCLC) cases  ≤ A], sen-
sitivity rates of 38–39% (AFP) and 46–48% (DCP) at 
about 95% specificity and in combination of 58–65% at a 
specificity near 90% were obtained. By ROC analysis, 
AUC values were similar for AFP (0.88) and DCP (0.87) 
and higher for their combination (0.91) for all HCC pa-
tients. For early-stage disease, AUC values were reduced 
for AFP (both 0.84) and DCP (0.81/0.79) and in combina-
tion to 0.87/0.80. This was in contrast to advanced stages 
(TNM >2 and BCLC >A) yielding higher values for AFP 
(0.92/0.90) and DCP (0.92/0.90) and in combination 
0.95/0.93. In patients with noncirrhotic HCC, AUC for 
DCP (0.93) significantly exceeded that for AFP (0.84) 
with no difference evident in cirrhotic HCC patients. Pos-
itive predictive values adjusted for their respective posi-
tive prevalence showed slightly higher values for DCP 
than for AFP and for all HCC than for early-stage HCC 
cases. They were all >30–40%, however, which was thus 
significant for attribution of a positive AFP and DCP test 
for HCC; in contrast, adjusted negative predictive values 
were below 10–20%, and were thus not relevant for the 
exclusion of HCC by a negative AFP or DCP test. Accord-
ing to linear regression analysis, besides a correlation of 
AFP and DCP with liver function (Model for End-Stage 
Liver Disease and Child-Turcotte-Pugh scores) and stag-
ing, liver enzymes (γGT, AST and ALT) correlated sig-
nificantly with the biomarkers (p < 0.0001) in both co-
horts, in contrast to a significant correlation only for AFP 
in early-stage disease and no correlation for either mark-
er with gender, age and etiology.
 A special item of the study is its focus on the increasing 
relevance of the risk of HCC in patients with nonalco-
holic fatty liver disease (NAFLD) which may progress to 
HCC even in the absence of apparent cirrhosis; this was 
already investigated by the authors in a former publica-
tion  [21] . The menace of HCC in NAFLD in the USA and 
Western countries has recently been described; it is stim-
ulated by increasing cases of obesity, metabolic syndrome 
and type 2 diabetes which lead to many alterations and 
molecular pathway disturbances  [22] . Furthermore, an 
AASLD practice guideline for the diagnosis and manage-
ment of NAFLD  [23]  was recently published, citing a 
worldwide prevalence of NAFLD ranging from 6.3 to 33% 
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cording to a Japanese review, NAFLD accounts for 1–5% 
of all HCC (male-predominant with a median age of 72 
years) and for 10–75% of HCC arising in noncirrhotic liv-
ers  [24] . In conclusion, the study by Ertle et al.  [20]  on the 
serological detection of HCC of varied etiology in Euro-
pean patients by use of a cut-off optimized measurement 
of AFP and DCP, with the relatively higher detection rate 
in NASH, alcoholic steatohepatitis, cryptogenic and non-
cirrhotic etiology cases, offers a valuable combination for 
HCC detection of viral and increasingly nonviral causes 
of this disease. Such detection includes early-stage disease 
which can ultimately result in patients benefitting from a 
more successful treatment procedure  [25] . 
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